AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

1,079.952

+16.9331.59%

Number of Gainers:11

Number of Losers:7

Number of Flat:14

PE:- -

High:1,082.055

Open:1,060.055

Low:1,059.594

Close:1,063.019

Loading ...

The five numbers that explain why Coles is beating Woolies

The Australian Financial Review

CSL Unit, US Partner Say European Commission Grants Marketing Authorization for Kidney Disease Treatment Drug

MT Newswires Live

Press Release: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

CSL Unit Awarded Contract by EU Regulator to Reserve 27 Million Flu Vaccine Doses

MT Newswires Live

This is the number one factor I look for when buying ASX dividend shares

Zoono Group Ltd - Improved Sales Revenues Expected in Q4 FY25 and Q1 FY26

THOMSON REUTERS

Coles - Qtrly Total Group Sales Revenue a$10,379 Mln

THOMSON REUTERS

Coles Group Ltd - in Early Part of Q4, Supermarkets Sales Growth Has Remained Broadly in Line With Q3

THOMSON REUTERS

How to turn $100 a week into $500,000 with ASX shares

This ASX medical device company has a Trump tariff exemption

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live

BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans

CSL Ltd - CSL Seqirus Signs Agreement With the European Commission to Support Pandemic Preparedness Plans

THOMSON REUTERS

Brokers tip 4 ASX 200 healthcare shares to buy now

Lark Distilling Co Ltd-Proposed Issue of Securities - Lrk

THOMSON REUTERS

Harris Technology Group - No Impact on Revenue From United States Tariffs Expected

THOMSON REUTERS

Harris Technology - Q3 FY25 Sales of a$3.3M

THOMSON REUTERS

3 blue chip ASX dividend stocks to buy and hold forever

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7501/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":1079.9519,"timestamp":1746165599592,"preClose":1063.0193,"halted":0,"volume":39874295,"delay":0,"changeRate":0.015929,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":16.932617,"latestTime":"05-02 16:00:00 AEST","open":1060.0554,"high":1082.0546,"low":1059.5944,"amount":375248669,"amplitude":0.021129,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746144000000,1746165600000]],"turnoverRate":0.002825,"increases":11,"decrements":8,"flats":14,"marketCap":275924881192.75,"floatMarketCap":225042184693.21094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1082.0546,"amplitude":0.021129,"preClose":1063.0193,"low":1059.5944,"latestPrice":1079.9519,"volume":39874295,"delay":0,"open":1060.0554,"prevYearClose":1117.913,"prevWeekClose":1031.533,"prevMonthClose":1052.524,"prevQuarterClose":1021.93,"fiveDayClose":1031.533,"twentyDayClose":1032.494,"sixtyDayClose":1089.922,"secType":"PLATE","market":"AU","turnoverRate":0.002825,"marketCap":275924881192.75,"floatMarketCap":225042184693.21094,"timestamp":1746165599592,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":11,"down":7,"flat":14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531252767","title":"The five numbers that explain why Coles is beating Woolies","url":"https://stock-news.laohu8.com/highlight/detail?id=2531252767","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531252767?lang=en_us&edition=fundamental","pubTime":"2025-04-30 10:00","pubTimestamp":1745978400,"startTime":"0","endTime":"0","summary":"You only need to look at Coles’ and Woolworths’ share prices to see how the gap between Australia’s supermarket powerhouses has opened up in the past 12 months: Woolworths’ stock has gone nowhere despite its obvious defensive qualities, while Coles is up more than 31 per cent.Five numbers contained in the March quarter sales chief executive Leah Weckert delivered on Wednesday help explain this divergence. For the moment at least, Team Down Down appears to be showing the Fresh Food People a clean pair of heels.Loading...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/chanticleer/the-five-numbers-that-explain-why-coles-is-beating-woolies-20250430-p5lvc5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["BK7040","BK7501","BK7082","BK7511","COL.AU","WOW.AU"],"gpt_icon":0},{"id":"2531774643","title":"CSL Unit, US Partner Say European Commission Grants Marketing Authorization for Kidney Disease Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774643","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531774643?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:57","pubTimestamp":1745974653,"startTime":"0","endTime":"0","summary":"CSL's  Switzerland-based pharmaceutical unit, CSL Vifor, and US biopharmaceutical firm Travere Therapeutics said the European Commission has granted standard marketing authorization for Filspari, a treatment for primary IgA nephropathy , a rare and progressive kidney disease, according to a Tuesday statement by the company.The decision converts a previous conditional marketing authorization and extends to all European Union member states, as well as Iceland, Liechtenstein, and Norway, the company said.Filspari was developed by Travere Therapeutics and exclusively licensed to CSL Vifor for commercialization in Europe, Australia, and New Zealand.CSL's shares rose 1% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CSL","CSL.AU","LU0728928796.USD","BK4086","SG9999004303.SGD","LU1169589451.USD","LU1169590202.USD","BK7511","BK7501","SGXZ23171101.USD","BK7508"],"gpt_icon":0},{"id":"2531746982","title":"Press Release: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531746982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531746982?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:53","pubTimestamp":1745974380,"startTime":"0","endTime":"0","summary":"NEW YORK, April 29, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.\"We were very pleased to have made Ryoncil  commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell  therapy approved in the US for any indication,\" said Dr. Silviu Itescu, CEO of Mesoblast. \"With our strong cash position we are well placed to expand Ryoncil indications to other serious and life-threatening pediatric inflammatory diseases, and to adults with acute GvHD.\". -- Net operating cash spend for the quarter was US$12.7 million.-- Cash on hand at the end of the quarter was US$182 million (A$290. -- Ryoncil became commercially available for purchase in the United. States on March 28, 2025, with Federal Medicaid coverage, and to date 15. infusion kits have been purchased for patients t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","R","BK7501","BK4526","BK4006","BK4150","BK4551","LU1363072403.SGD","BK4139","MESO","BK4141","IE00BKVL7J92.USD","CMC","DDD","BK4232","LU0267386448.USD","BK7508","MSC","MSB","BK4585","BK4170","BK4588","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","BK4161","BK4604","LU0170899867.USD","TM","BK4575","BK4555","03160","BK4546","IE00BHPRN162.USD","BK4022","LU0149725797.USD","LU0971096721.USD","MSB.AU","BK4543","LU0882574139.USD","BK7067","ASX"],"gpt_icon":0},{"id":"2531774308","title":"CSL Unit Awarded Contract by EU Regulator to Reserve 27 Million Flu Vaccine Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774308","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531774308?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:31","pubTimestamp":1745973088,"startTime":"0","endTime":"0","summary":"CSL  said Tuesday CSL Seqirus was awarded a contract by the Health Emergency Preparedness and Response Authority to support the pandemic preparedness plans of 17 European Union and European Economic Area member states as well as the European Commission.Under the contract, 27 million doses of pandemic influenza vaccine have been reserved with CSL Seqirus, which can be ordered by the participating countries in the event of an influenza pandemic, according to a statement.The deal requires CSL Seqirus to be prepared to rapidly manufacture and deliver these vaccine doses. The doses will be produced at the company's manufacturing site in Liverpool, UK.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","SGXZ23171101.USD","LU1169590202.USD","LU1169589451.USD","BK7501","BK7511","CSL.AU","BK7067","LU0728928796.USD","BK4086","CSL","BK7508","SG9999004303.SGD"],"gpt_icon":0},{"id":"2531108157","title":"This is the number one factor I look for when buying ASX dividend shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531108157","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531108157?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:30","pubTimestamp":1745969400,"startTime":"0","endTime":"0","summary":"ASX dividend shares can be great investments. However, there's a particular factor that I look for the most when it comes to passive income.  When it comes to businesses that paydividends, there are various elements to consider. How big is the dividend yield?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/this-is-the-number-one-factor-i-look-for-when-buying-asx-dividend-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7040","BK7095","SHL.AU","BK7094","NAB.AU","WBC.AU","PME.AU","SOL.AU","ANZ.AU","BK7083","BKW.AU","FMG.AU","BK7501","BK7503","BK7135","BK7082","WTC.AU","BK7507","TNE.AU","COL.AU","BK7016","RIO.AU","BK7105","BK7511","BHP.AU","BK7124","BK7044","BK7129"],"gpt_icon":0},{"id":"2531915712","title":"Zoono Group Ltd - Improved Sales Revenues Expected in Q4 FY25 and Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2531915712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531915712?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:17","pubTimestamp":1745968638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R725D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","ZNO.AU","BK7036"],"gpt_icon":0},{"id":"2531711364","title":"Coles - Qtrly Total Group Sales Revenue a$10,379 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2531711364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531711364?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:43","pubTimestamp":1745966590,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nPLX09113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7040","COL.AU","BK7082","BK7501"],"gpt_icon":0},{"id":"2531384711","title":"Coles Group Ltd - in Early Part of Q4, Supermarkets Sales Growth Has Remained Broadly in Line With Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2531384711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531384711?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:42","pubTimestamp":1745966553,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R727L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COL.AU","BK7040","BK7501","BK7082"],"gpt_icon":0},{"id":"2531071038","title":"How to turn $100 a week into $500,000 with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531071038","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531071038?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:15","pubTimestamp":1745964914,"startTime":"0","endTime":"0","summary":"Investing can seem daunting at first — especially if you're starting small. But here's the good news: you don't need a huge salary, a stock-picking superpower, or perfect timing to build serious wealt","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/how-to-turn-100-a-week-into-500000-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WTC.AU","BK7067","CSL.AU","RMD.AU","BK7041","BK7007","WES.AU","BK7508","VGS.AU","BK7503","BK7501","BK7511","IVV.AU","BK7153","BK7016"],"gpt_icon":0},{"id":"2531716526","title":"This ASX medical device company has a Trump tariff exemption","url":"https://stock-news.laohu8.com/highlight/detail?id=2531716526","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531716526?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:01","pubTimestamp":1745964084,"startTime":"0","endTime":"0","summary":"It seems brokers are bullish on this blue-chip stock, with multiple brokers placing attractive price targets on the stock thanks to the tariff exemption and strong financials. At the time of writing, shares are trading at $36.75 each. Macquarie has a price target $48.00, indicating a 30% upside. Analysts at Goldman Sachs have retained their conviction buy rating on ResMed shares with an improved price target of $49.30.This was also influenced by the tariff exemption.  Jed Richards from Shaw and Partners says Resmed is a buy. Richards said: On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent. ResMed's innovative products and steady revenue growth make it a solid investment. Bell Potter has a $43.31 price target.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/this-asx-medical-device-company-has-a-trump-tariff-exemption/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","XKO.AU","XJO.AU","BK7007","XAO.AU","RMD.AU"],"gpt_icon":0},{"id":"2531512517","title":"Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531512517","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531512517?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:51","pubTimestamp":1745938294,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) and CSL Vifor said Tuesday that the European Commission has converted the conditional marketing approval of Filspari into a standard marketing authorization for the treatme","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK7511","BK7501","BK4156","BK7508","BK7067","LU1169590202.USD","SGXZ23171101.USD","BK4139","TVTX","CSL.AU","CSL","LU0728928796.USD","BK4086","LU1169589451.USD"],"gpt_icon":0},{"id":"2531769785","title":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531769785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531769785?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:58","pubTimestamp":1745924321,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness PlansApril 29  - CSL Ltd CSL.AX:CSL SEQIRUS SIGNS  AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPORT PANDEMIC PREPAREDNESS PLANSFurther company coverage: CSL.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2531120074","title":"CSL Ltd - CSL Seqirus Signs  Agreement With the European Commission to Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531120074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531120074?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:30","pubTimestamp":1745922653,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7511","BK7501","BK7508","CSL.AU"],"gpt_icon":0},{"id":"2531227449","title":"Brokers tip 4 ASX 200 healthcare shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2531227449","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531227449?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:05","pubTimestamp":1745910347,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index  lifting 0.61%.  Healthcare is seen as a defensive sector.  In today's turbulent market, perhaps you might be looking for buying opportunities?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/brokers-tip-4-asx-200-healthcare-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7124","CSL.AU","BK7067","BK7007","BK7501","HLS.AU","TLX.AU","BK7509","RMD.AU","BK7508","BK7511"],"gpt_icon":0},{"id":"2531422945","title":"Lark Distilling Co Ltd-Proposed Issue of Securities - Lrk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531422945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531422945?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:39","pubTimestamp":1745908797,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUE5LLCMT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7097","LRK.AU"],"gpt_icon":0},{"id":"2531522997","title":"Harris Technology Group - No Impact on Revenue From United States Tariffs Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2531522997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531522997?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:37","pubTimestamp":1745908668,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7001","BK7501","BK7049","HT8.AU"],"gpt_icon":0},{"id":"2531229929","title":"Harris Technology - Q3 FY25 Sales of a$3.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2531229929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531229929?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:37","pubTimestamp":1745908668,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62GN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7001","BK7049","HT8.AU"],"gpt_icon":0},{"id":"2531750525","title":"3 blue chip ASX dividend stocks to buy and hold forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2531750525","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531750525?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:08","pubTimestamp":1745906914,"startTime":"0","endTime":"0","summary":"When it comes to building a resilient, long-term investment portfolio, blue chip ASX dividend stocks are hard to beat. These are the companies with strong balance sheets, reliable cash flows, and a track record of rewarding shareholders through good times and bad. They provide the rare combination of steady income and capital stability — making them ideal for investors who want to grow their wealth steadily without sleepless nights. But which blue chips would make good buy and hold picks for income investors?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/3-blue-chip-asx-dividend-stocks-to-buy-and-hold-forever/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0267386448.USD","LU1668664300.SGD","LU0098860793.USD","LU0912757837.SGD","LU0106261372.USD","LU0158827948.USD","LU1989772840.SGD","LU2111349929.HKD","TLS.AU","COL.AU","BK4534","LU1732799900.SGD","XAO.AU","LU0225283273.USD","LU1720051108.HKD","BK7040","LU1989772923.USD","BK4581","BK4585","LU0795875169.SGD","LU2089284900.SGD","BK7042","BK7082","LU1162221912.USD","BK4588","BK4127","LU0320765646.SGD","LU1720051017.SGD","LU0006306889.USD","LU2089283258.USD","BK7511","XKO.AU","LU1732800096.USD","IE00BZ1G4Q59.USD","LU2347655156.SGD","BK7046","LU0795875086.SGD","LU0106831901.USD","LU2028103732.USD","MQG.AU","LU2271345857.HKD","LU1363072403.SGD","BK7501","LU2357305700.SGD","LU0314104364.USD","XJO.AU","BK4504","BK4516","LU2023251221.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2531225933","title":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225933","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225933?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:04","pubTimestamp":1745906694,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari In Iga NephropathyApril 29 (Reuters) - CSL Ltd CSL.AX:CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK4139","CSL.AU","BK7508","BK7511","TVTX"],"gpt_icon":0},{"id":"2531225879","title":"CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225879?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:01","pubTimestamp":1745906478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVTX","BK7508","BK7501","BK7511","CSL.AU","BK4139","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":102,"code":"91000000","status":"200"}]}}